New drug applications approved by US FDA as of 01 - 15 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Dual triggering with a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) may increase the number of oocytes among women undergoing in vitro fertilization (IVF), according to a study presented at ESHRE 2018.
Fewer children, older age at menarche, and a higher number of miscarriages are among factors that may raise a woman’s risk of dementia, according to a study presented at the recent Alzheimer’s Association International Conference (AAIC 2018).
While the use of a mesh for pelvic organ prolapse repair resulted in an elevated risk of repeat surgery compared with native tissue repair, the mesh itself did not influence the need for repeat procedure, according to a US-based study.
Use of aspirin or NSAIDs after the diagnosis of ovarian cancer appears to improve ovarian cancer-specific survival, according to data from the ongoing Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII).
Endometrial scratching prior to in vitro fertilization (IVF) failed to improve live birth rates in the PIP* study, challenging a practice currently embraced by gynaecologists to boost the chances of embryo implantation in subfertile women.
Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.